- Home
- LIPO vs KTTA Comparison
LIPO vs KTTA Comparison
Compare LIPO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- KTTA
- Stock Information
- Founded
- LIPO 2005
- KTTA 2020
- Country
- LIPO United States
- KTTA United States
- Employees
- LIPO N/A
- KTTA N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- KTTA Health Care
- Exchange
- LIPO Nasdaq
- KTTA Nasdaq
- Market Cap
- LIPO 3.1M
- KTTA 2.8M
- IPO Year
- LIPO 2022
- KTTA 2021
- Fundamental
- Price
- LIPO $2.99
- KTTA $0.89
- Analyst Decision
- LIPO
- KTTA
- Analyst Count
- LIPO 0
- KTTA 0
- Target Price
- LIPO N/A
- KTTA N/A
- AVG Volume (30 Days)
- LIPO 39.2K
- KTTA 2.3M
- Earning Date
- LIPO 05-14-2025
- KTTA 05-15-2025
- Dividend Yield
- LIPO N/A
- KTTA N/A
- EPS Growth
- LIPO N/A
- KTTA N/A
- EPS
- LIPO N/A
- KTTA N/A
- Revenue
- LIPO $519,866.00
- KTTA N/A
- Revenue This Year
- LIPO N/A
- KTTA N/A
- Revenue Next Year
- LIPO N/A
- KTTA N/A
- P/E Ratio
- LIPO N/A
- KTTA N/A
- Revenue Growth
- LIPO 8.88
- KTTA N/A
- 52 Week Low
- LIPO $1.97
- KTTA $0.79
- 52 Week High
- LIPO $12.00
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- LIPO 58.50
- KTTA 38.94
- Support Level
- LIPO $2.75
- KTTA $0.87
- Resistance Level
- LIPO $3.17
- KTTA $0.95
- Average True Range (ATR)
- LIPO 0.29
- KTTA 0.07
- MACD
- LIPO 0.02
- KTTA 0.01
- Stochastic Oscillator
- LIPO 81.05
- KTTA 40.41
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).